China Pharmaceutical Park Series: the rising "Suzhou biomedical industrial park"!

Suzhou biomedical industrial park, as one of the few national industrial parks in China, has a very high concentration of pharmaceutical innovation industry A number of domestic innovative drug R & D star enterprises have been born, such as Xinda biology, cornerstone pharmaceutical, etc Moreover, in 2017, the park's biomedical output value exceeded rmb63 billion, with strong growth, and it is rapidly growing into a national park as famous as Zhangjiang Pharmaceutical Industrial Park in Shanghai! 1 Suzhou biomedical industrial park - brief introduction: Suzhou biomedical industrial park (blobay), located in Dushu Lake Science and Education Innovation Zone of Suzhou Industrial Park, is the main innovation base for cultivating the development of biotechnology industry in Suzhou Industrial Park At present, it has gathered more than 10000 high-level R & D talents and more than 400 independent innovative biomedical enterprises It has initially formed a R & D innovative industrial cluster focusing on new drug innovation, medical devices, biotechnology, service outsourcing and nanotechnology, and has become an innovation community for high-level talent R & D gathering, exchange and cooperation The first phase of Suzhou biomedical industrial park is located in the former Suzhou Biological Nanotechnology park; the second phase of Suzhou biomedical industrial park is located in santian street of Suzhou Industrial Park; and the second phase of Suyu biomedical industrial park is located in Haiyu Town, Changshu City, Jiangsu Province 2 development timeline of the park In March 2006, the construction of Suzhou Biological Nanotechnology Park started; in 2007, the opening ceremony of Suzhou Biological Nanotechnology Park was held, and the first public technology service platform drug analysis and testing platform was completed and put into operation; in 2010, the related cooperation project of cold spring port Laboratory of the United States was unveiled, and Suzhou Biological Nanotechnology Park was promoted to a national science and technology enterprise incubator; 201 In 2013, Kaijie transformation medical center, the first domestic commercial operation organization with transformation medicine as the core, officially put into operation, and Suyu biomedical industrial park officially laid the foundation; in 2014, Suzhou Gemma gene Co., Ltd became the first listed enterprise in the third edition of Suzhou Biological Nanotechnology park; in 2016, Baiji Shenzhou officially launched Landing on NASDAQ became the first IPO in 2016 in the United States, and Dongyao pharmaceutical signed a commissioned research and production contract with Suzhou development Pharmaceutical Co., Ltd became the first MAH system in Suzhou.. 3 Park incentive policies In March 2018, the Management Committee of Suzhou Industrial Park issued the implementation measures of Suzhou Industrial Park on further promoting the development of biomedical industry The items about encouraging innovation are as follows: $~ Article 2 encourage the registration and application of new drugs and realize industrialization in the park For the first category of chemical drugs, the first to the third category of biological products for treatment, the first category of biological products for prevention, the first to the sixth category of traditional Chinese medicine and natural products, rewards will be given according to the achievements before and after the clinical stage and the contribution of the actual sales of products to the local finance of the park: the enterprise conducts the pre clinical safety evaluation research, and after the completion of the relevant research, rewards of up to 1 million yuan will be given according to the actual costs If the enterprise completes the preclinical research of drugs, applies for clinical application and receives the acceptance, it will be rewarded with 1 million yuan; if the enterprise completes the preclinical research of drugs, it will be rewarded with 1 million yuan for the approval documents of clinical trials; if the enterprise completes the first and second phase clinical trials of drugs, it will be rewarded with a maximum of 500000 yuan according to the actual trial costs; if the enterprise completes the third phase clinical trials, it will be applied for production or new application If the drug certificate is accepted, RMB 800000 will be awarded Article 6 enterprises are encouraged to actively apply for international and domestic certification For the new drugs researched and developed by the enterprise, if they are registered by FDA, EMA or EDQM, and realize industrialization in the park, a one-time reward of up to 1 million yuan will be given according to the actual amount 4 star pharmaceutical enterprises in the park, for example, Xinda bio Xinda bio, founded in 2011, is committed to the development, production and sale of innovative drugs for the treatment of major diseases such as cancer On October 31, 2018, Cinda bio pharmaceutical was listed on the main board of Hong Kong stock exchange with the stock code of 01801 The research fields mainly cover tumor, fundus disease, autoimmune disease, cardiovascular disease, etc., among which 4 varieties are selected into the national "major new drug creation" special project, 14 varieties are in clinical research, 4 varieties are in clinical phase III research, 2 McAb products are accepted by the State Drug Administration and included in the priority review, 1 product (cindili McAb injection, trade name: Dabo Shu ®, English trademark: tyvyt ®) has been approved by the State Drug Administration for marketing The first approved indication is relapsed / refractory classic Hodgkin's lymphoma The cornerstone pharmaceutical industry (HKEx: 2616), a biopharmaceutical company, focuses on the development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the keen medical needs of cancer patients in China and the world Founded at the end of 2015, in April 2016, cornerstone pharmaceutical was registered in Suzhou In October 2017, the first phase I clinical trial of natural full-length, all human anti-PD-L1 monoclonal antibody cs1001 was started and completed in China; in June 2018, two phase II clinical trials of PD-L1 monoclonal antibody cs1001 were started and completed in China; in August 2018, CTLA-4 monoclonal antibody cs1002 obtained the clinical trial approval in China; in September 2018, PD-L1 monoclonal antibody C S1001 clinical trial application was approved by FDA of the United States; in October 2018, PD-1 McAb cs1003 clinical trial application was approved by FDA of the United States In 2010, Baiji Shenzhou was founded in Beijing as a research and development company In 2011, the R & D center was established in Beijing to launch the small molecule development project, and the team members expanded to more than 100; in 2013, the cooperation with Merck xuelanuo started with lifirafinib and pamiparib, and the clinical trial was carried out in Australia; in 2016, the company became the first IPO of US stock in that year, completed the financing of US $212 million, and started to build Suzhou production base; in 2018, the company successfully conducted the joint stock exchange in Hong Kong Our company is mainly listed on the market and announced the commercial supply of vidasha in China, as well as the approval of rifeme for the treatment of newly diagnosed multiple myeloma patients Summary & when it comes to Suzhou biomedical industrial park, Xiaogan will naturally remind people of Zhangjiang, Shanghai! Compared with Zhangjiang hi tech, Suzhou biomedical industrial park is more young and has more development potential It is the leader of national biomedical parks in recent years! In recent years, many foreign large pharmaceutical companies, such as GlaxoSmithKline, Lilly, Weicai and Johnson & Johnson, have also settled in the park, which fully confirms the overall development potential of the park! Suzhou is also a great place for high-end talents who are committed to the development of medicine, whether in work or life! Adopt the medical health big data application cooperation incubation mode, use the "data application, service entrepreneurship and innovation, project incubation, docking Park" four in one incubation mode to provide big data application, consulting service, academic conference, medical exhibition, talent service, entrepreneurship guidance, project roadshow, policy analysis, financing investment, public technology service platform, marketing and publicity for the park and enterprises And other service projects to provide multi-functional one-stop service for innovation and Entrepreneurship of the pharmaceutical and health industry park Click the link: https://gu.yaozh.com/ to enter the "medicine and health park service expert - medicine and wisdom Valley statement: this view only represents the author, not the position of medicine and wisdom network, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.